CMS approves coverage for Dexcom G6 CGM, the only CGM system recognized by Medicare that offers mobile device compatibility and no fingerstick calibration
SAN DIEGO – October 18, 2018 – DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM), announced today the new Dexcom G6® CGM System will be covered for Medicare beneficiaries, having met the category requirements for therapeutic CGM systems by the U.S. Centers for Medicare & Medicaid Services (CMS). Coverage for therapeutic CGM includes certain beneficiaries who have either Type 1 or Type 2 diabetes and intensively manage their insulin. The company expects to begin shipping product to Medicare customers in the first part of 2019.
“The Dexcom G6 is a game-changer for people with diabetes, and we are thrilled to provide this innovative technology to the many Americans with diabetes who rely on Medicare,” said Kevin Sayer, President and CEO of Dexcom. “With the CMS policy coverage, Medicare beneficiaries with diabetes who use G6 will no longer require fingersticks to make treatment decisions or calibrate their CGM.”
The new Dexcom G6 boasts a number of features that make it a very powerful diabetes management tool.
Who is covered?
According to CMS, therapeutic CGM may be covered by Medicare when all of the following criteria are met:
How to get the Dexcom G6? It’s easy.
CGM devices are considered one of the most significant breakthroughs in diabetes management in the past 40 years1., and Dexcom has been a leader of those innovations. Diabetes affects nearly 30 million Americans and is the seventh leading cause of death in the United States2. The traditional standard-of-care for glucose monitoring has been a fingerstick meter, which is painful as some people with diabetes needed to test their blood up to 12 times a day. CGM is important because, in addition to providing the glucose level, it provides the direction and rate of glucose change with the push of a button and alerts users when glucose levels are too low or too high. People with diabetes who take insulin must monitor their blood glucose levels frequently. Uncontrolled glucose can cause health complications and even death3. , 4.. To learn more about CGM, visit www.dexcom.com.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric people with diabetes. With exceptional performance, comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty. For more information on the Dexcom CGM, visit www.dexcom.com.
Steve Pacelli, 858-200-0200
James McIntosh, 619-884-2118
1. Clarke SF and Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;(3)2:83-93.
2. 2014 National Diabetes Statistics Report. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf Accessed March 31, 2015.
3. Hyperglycemia (High blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html. Updated August 5, 2013. Accessed December 3, 2013.
4. Hypoglycemia (Low blood glucose). American Diabetes Association Web site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html. Updated July 16, 2013. Accessed December 3, 2013.
Our Chairman and CEO, Kevin Sayer, was on Mad Money with Jim Cramer to discuss our CGM technology and the successful year Dexcom had in 2018.
November is National Diabetes Awareness Month, a time when communities across the country bring attention to the impact and treatment of diabetes.